ENVB
HEALTHCAREEnveric Biosciences Inc
AI Insight
What's Moving ENVB Today?
No stock-specific AI insight has been generated for ENVB yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.26$17.64
$1.31
Fundamentals
Market Cap$5M
P/E Ratio—
EPS$-22.74
Dividend Yield—
Dividend / Share—
ROE-183.1%
Profit Margin—
Debt / Equity—
Trading
Volume163K
Avg Volume (10D)—
Shares Outstanding4.0M
ENVB News
23 articles- Enveric Biosciences Announces Participation in 2026 BIO International ConventionInvesting News Network·Jun 16, 2026
- Enveric Biosciences to Participate in the UBS 3rd Virtual CNS DayYahoo Finance·Jun 9, 2026
- Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003Yahoo Finance·Jun 2, 2026
- Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003Yahoo Finance·May 19, 2026
- Enveric (ENVB) Secures $13.9 Million in Private Placement FundinGuruFocus·May 15, 2026
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026Investing News Network·May 15, 2026
- Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric DisordersYahoo Finance·May 13, 2026
- TradingKeyTradingKey·May 12, 2026
- Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical ModelYahoo Finance·May 5, 2026
- Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of DirectorsYahoo Finance·Apr 28, 2026
- Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics ForumYahoo Finance·Apr 21, 2026
- Enveric Biosciences Stock Soars After Trump's Psychedelics Executive OrderBenzinga·Apr 20, 2026
- Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 17, 2026
- Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Apr 17, 2026
- Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug CandidatesYahoo Finance·Mar 31, 2026
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025Yahoo Finance·Mar 27, 2026
- Enveric Biosciences Announces Registration of Five TrademarksYahoo Finance·Mar 18, 2026
- Enveric Biosciences Announces Withdrawal of Petition Against Its PatentYahoo Finance·Feb 25, 2026
- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Feb 23, 2026
- Enveric Biosciences reports EB-003 receptor engagement assay dataYahoo Finance·Feb 20, 2026
- Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay DataYahoo Finance·Feb 19, 2026
- Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and OptionYahoo Finance·Jan 29, 2026
- Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesYahoo Finance·Jan 28, 2026
All 23 articles loaded
Price Data
Open$1.41
Previous Close$1.35
Day High$1.41
Day Low$1.31
52 Week High$17.64
52 Week Low$1.26
52-Week Range
$1.26$17.64
$1.31
Fundamentals
Market Cap$5M
P/E Ratio—
EPS$-22.74
Dividend Yield—
Dividend / Share—
ROE-183.1%
Profit Margin—
Debt / Equity—
Trading
Volume163K
Avg Volume (10D)—
Shares Outstanding4.0M
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a pharmaceutical company, is dedicated to developing various cannabinoid drugs for the treatment of cancer. The company is headquartered in Naples, Florida.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—